HC Wainwright & Co. Maintains Buy on Disc Medicine, Raises Price Target to $127
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Douglas Tsao maintains Disc Medicine (NASDAQ:IRON) with a Buy and raises the price target from $120 to $127.
HC Wainwright & Co. analyst Douglas Tsao maintains Disc Medicine (NASDAQ:IRON) with a Buy and raises the price target from $120 to $127.
